EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer

Melissa Maxwell, Dingxue Yan, Brianna Rivest, Andrew Boone, James Cardia, Elfriede Noessner

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03835-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Melissa Maxwell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Phio Pharmaceuticals, 11 Apex Dr., Ste 300A PMB 2006, Marlborough, MA, 01752, USA. mmaxwell@phiopharma.com. Hauptthemen laut MEDLINE: Killer Cells, Natural, Receptors, Immunologic, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are frontline defenders against cancer and are capable of recognizing and eliminating tumor cells without prior sensitization or antigen presentation. Due to their unique HLA mismatch tolerance, they are ideal for adoptive cell therapy (ACT) because of their ability to minimize graft-versus-host-disease risk. The therapeutic efficacy of NK cells is limited in part by inhibitory immune checkpoint receptors, which are upregulated upon interaction with cancer cells and the tumor microenvironment. Overexpression of inhibitory receptors reduces NK cell-mediated cytotoxicity by impairing the ability of NK cells to secrete effector cytokines and cytotoxic granules. T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), a well-known checkpoint receptor involved in T-cell exhaustion, has recently been implicated in the exhaustion of NK cells. Overcoming TIGIT-mediated inhibition of NK cells may allow for a more potent antitumor response following ACT. Here, we describe a novel approach to TIGIT inhibition using self-delivering RNAi compounds (INTASYL™) that incorporates the features of RNAi and antisense technology. INTASYL compounds demonstrate potent activity and stability, are rapidly and efficiently taken up by cells, and can be easily incorporated into cell product manufacturing. INTASYL PH-804, which targets TIGIT, suppresses TIGIT mRNA and protein expression in NK cells, resulting in increased cytotoxic capacity and enhanced tumor cell killing in vitro. Delivering PH-804 to NK cells before ACT has emerged as a promising strategy to counter TIGIT inhibition, thereby improving the antitumor response. This approach offers the potential for more potent off-the-shelf products for adoptive cell therapy, particularly for hematological malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalReceptors, ImmunologicImmunotherapy, AdoptiveNeoplasmsHumansCytotoxicity, ImmunologicRNA InterferenceCell Line, TumorRNA, Small Interfering

Stichwörter der Autor:innen

Adoptive cell therapy (ACT)NK cellsRNAiTIGIT

Substanzen

Receptors, ImmunologicTIGIT protein, humanRNA, Small Interfering

Autor:innen und Institutionen

  • Phio Pharmaceuticals, 11 Apex Dr., Ste 300A PMB 2006, Marlborough, MA, 01752, USA. mmaxwell@phiopharma.com.
  • Phio Pharmaceuticals, 11 Apex Dr., Ste 300A PMB 2006, Marlborough, MA, 01752, USA.
  • Immunoanalytics-Tissue Control of Immunocytes, Helmholtz Zentrum Munich, Feodor-Lynen-Str. 21, 81377, Munich, Germany.

Zitieren

APA

Maxwell, M., Yan, D., Rivest, B., Boone, A., Cardia, J., & Noessner, E. (2024). INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03835-x

Vancouver

Maxwell M, Yan D, Rivest B, Boone A, Cardia J, Noessner E. INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03835-x

BibTeX
@article{Maxwell2024,
  author = {Maxwell, Melissa and Yan, Dingxue and Rivest, Brianna and Boone, Andrew and Cardia, James and Noessner, Elfriede},
  title = {INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03835-x}
}
Kostenlos starten →